BTIG analyst Julian Harrison maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) yesterday and set a price target of $4.00.
Julian Harrison has given his Buy rating due to a combination of factors that highlight Nektar Therapeutics’ promising pipeline and strategic positioning in the market. The upcoming Phase 2b trial results for REZPEG in atopic dermatitis, expected in June 2025, are a significant focus. Harrison sees this as a potential breakthrough, especially given the recent setbacks faced by competitors in similar trials, which Nektar has strategically mitigated against by ensuring rigorous trial criteria and diverse enrollment.
Furthermore, REZPEG’s potential in alopecia areata and the planned studies in Type 1 diabetes, supported by TrialNet, add to the optimism. Beyond REZPEG, Nektar’s rights to dapirolizumab and NKTR-0165 present additional growth opportunities. The company’s strong cash position, sufficient to fund operations into late 2026, further supports the Buy rating, indicating financial stability and the ability to continue advancing their pipeline.
Harrison covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Nektar Therapeutics, and Spyre Therapeutics. According to TipRanks, Harrison has an average return of 2.3% and a 39.75% success rate on recommended stocks.
In another report released on February 28, B.Riley Financial also reiterated a Buy rating on the stock with a $4.00 price target.